About Enhancer
| Enhancer ID: | E_01_0775 |
| Species: | human |
| Position : | chr11:32384746-32386746   |
| Biosample name: | |
| Experiment class : | High+Lowthroughput |
| Enhancer type: | Enhancer |
| Disease: | Acute myeloid leukemia (aml) |
| Pubmed ID: | 30082223 |
| Enhancer experiment: | Statistical analysis, PCR |
| Enhancer experiment description: | The WT1 protein is a unique transcription factor that can activate or repress target promoters depending on the cellular cofactors it binds to.3 More than 70% of patients with acute myelogenous leukemia (AML) will have overexpression of WT1 at diagnosis. 4-7 Whether the WT1 transcript levels at diagnosis are predictive of the outcomes of AML patients is controversial. |
About Target gene
| Target gene : | WT1(AWT1,GUD,NPHS4,WAGR,WIT-2,WT33),NPM1 |
| Strong evidence: | qRT-PCR,qPCR,ChIP,3C |
| Less strong evidence: | RNA-Seq |
| Target gene experiment description: | The WT1 protein is a unique transcription factor that can activate or repress target promoters depending on the cellular cofactors it binds to.3 More than 70% of patients with acute myelogenous leukemia (AML) will have overexpression of WT1 at diagnosis. 4-7 Whether the WT1 transcript levels at diagnosis are predictive of the outcomes of AML patients is controversial.;The WT1 protein is a unique transcription factor that can activate or repress target promoters depending on the cellular cofactors it binds to.3 More than 70% of patients with acute myelogenous leukemia (AML) will have overexpression of WT1 at diagnosis. 4-7 Whether the WT1 transcript levels at diagnosis are predictive of the outcomes of AML patients is controversial.;The WT1 protein is a unique transcription factor that can activate or repress target promoters depending on the cellular cofactors it binds to.3 More than 70% of patients with acute myelogenous leukemia (AML) will have overexpression of WT1 at diagnosis. 4-7 Whether the WT1 transcript levels at diagnosis are predictive of the outcomes of AML patients is controversial. |
About TF
| TF name : | CEBPA(C/EBP-alpha,CEBP) |
| TF experiment: | ????,PCR |
| TF experiment description: | The WT1 protein is a unique transcription factor that can activate or repress target promoters depending on the cellular cofactors it binds to.3 More than 70% of patients with acute myelogenous leukemia (AML) will have overexpression of WT1 at diagnosis. 4-7 Whether the WT1 transcript levels at diagnosis are predictive of the outcomes of AML patients is controversial.;The WT1 protein is a unique transcription factor that can activate or repress target promoters depending on the cellular cofactors it binds to.3 More than 70% of patients with acute myelogenous leukemia (AML) will have overexpression of WT1 at diagnosis. 4-7 Whether the WT1 transcript levels at diagnosis are predictive of the outcomes of AML patients is controversial.;The WT1 protein is a unique transcription factor that can activate or repress target promoters depending on the cellular cofactors it binds to.3 More than 70% of patients with acute myelogenous leukemia (AML) will have overexpression of WT1 at diagnosis. 4-7 Whether the WT1 transcript levels at diagnosis are predictive of the outcomes of AML patients is controversial. |
About Function
| Enhancer function : | The WT1 protein is a unique transcription factor that can activate or repress target promoters depending on the cellular cofactors it binds to.3 More than 70% of patients with acute myelogenous leukemia (AML) will have overexpression of WT1 at diagnosis. 4-7 Whether the WT1 transcript levels at diagnosis are predictive of the outcomes of AML patients is controversial. |
| Enhancer function experiment: | Immunohistochemical staining |
| Enhancer function experiment description: |
The WT1 protein is a unique transcription factor that can activate or repress target promoters depending on the cellular cofactors it binds to.3 More than 70% of patients with acute myelogenous leukemia (AML) will have overexpression of WT1 at diagnosis. 4-7 Whether the WT1 transcript levels at diagnosis are predictive of the outcomes of AML patients is controversial. |
About SNP
| SNP ID: | rs16754 |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| CEBPA | AndrogenReceptor | netpath | 167 |
| CEBPA | C-MYB transcription factor network | pid | 87 |
| CEBPA | E2F transcription factor network | pid | 77 |
| CEBPA | EGFR1 | netpath | 475 |
| CEBPA | FOXA2 and FOXA3 transcription factor networks | pid | 45 |
| CEBPA | IL4 | netpath | 75 |
| CEBPA | Regulation of Androgen receptor activity | pid | 54 |
| CEBPA | Regulation of retinoblastoma protein | pid | 67 |
| CEBPA | Transcriptional regulation of white adipocyte differentiation | reactome | 79 |
| CEBPA | Validated targets of C-MYC transcriptional repression | pid | 63 |
| CEBPA | Pathways in cancer | kegg | 321 |
| CEBPA | Acute myeloid leukemia | kegg | 53 |
| CEBPA | Hs_Regulation_of_Actin_Cytoskeleton_WP51_79977 | wikipathways | 36 |
| CEBPA | Hs_Pathways_Affected_in_Adenoid_Cystic_Carcinoma_WP3651_89271 | wikipathways | 27 |
| CEBPA | Hs_Nucleotide_Metabolism_WP404_68960 | wikipathways | 16 |
| CEBPA | Hs_Transcription_factor_regulation_in_adipogenesis_WP3599_88581 | wikipathways | 9 |
Enhancer associated network
The number on yellow line represents the distance between enhancer and
target gene